Todd DeVries - Concepedia

Author

Todd DeVries

Also Known As

S. Bursell, T A DeVries, T DEVRIES, T. A. DeVries, T. DeVries, T. Devries, Todd A Devries, Todd A. DeVries, Todd DeVries, Todd Devries

108

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

City of Hope University of California, San Francisco Dendreon (United States)Memorial Sloan Kettering Cancer Center University of Alabama at Birmingham

About

Todd DeVries is an author at City of Hope specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	328
2	Health Sciences	4	4	93
3	Clinical Immunology	3	3	145
4	Allergy	2	2	133
5	Cellular Therapies	1	1	121

Todd DeVries

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
Once‐weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trial Edward Keystone, Michael Schiff, Joel M. Kremer, Arthritis & Rheumatism	2004	286
Phase I Study of Recombinant Interleukin-21 in Patients With Metastatic Melanoma and Renal Cell Carcinoma John A. Thompson, Brendan D. Curti, Bruce G. Redman, Journal of Clinical Oncology	2008	184
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome Debraj GuhaThakurta, Nadeem A. Sheikh, Li-Qun Fan, Clinical Cancer Research	2015	130
JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE) Sham Mailankody, Myo Htut, Kelvin P. Lee, Blood	2018	124
Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). Sham Mailankody, Andrzej Jakubowiak, Myo Htut, Journal of Clinical Oncology Clinical ImmunologyCell TherapyImmunodeficienciesImmunologyImmune Regulation	2020	121
A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer Eric J. Small, Raymond S. Lance, Thomas A. Gardner, Clinical Cancer Research	2015	84
Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial Emmanuel S. Antonarakis, Adam S. Kibel, Evan Y. Yu, Clinical Cancer Research	2016	77
Clonotypic Diversification of Intratumoral T Cells Following Sipuleucel-T Treatment in Prostate Cancer Subjects Nadeem A. Sheikh, Jason Cham, Li Zhang, Cancer Research	2016	59
The Impact of Restrictive Entry Criterion During the Placebo Lead‐in Period Ronald J. Landin, David J. DeBrota, Todd DeVries, Biometrics Placebo ResponseTreatment EffectLead IdentificationPharmacotherapyMental Health	2000	55
A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T Douglas G. McNeel, Thomas A. Gardner, Celestia S. Higano, Cancer Immunology Research Transient IncreaseUrologySipuleucel-t TreatmentGenitourinary CancerMedicine	2014	52

Page 1